Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Risk and protective factors for COVID-19 morbidity, severity, and mortality
J Zhang, X Dong, G Liu, Y Gao - Clinical reviews in allergy & immunology, 2023 - Springer
The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global …
Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
Mechanisms of SARS-CoV-2 entry into cells
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
Sex and gender in asthma
Asthma is a heterogenous disease, and its prevalence and severity are different in males
versus females through various ages. As children, boys have an increased prevalence of …
versus females through various ages. As children, boys have an increased prevalence of …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
ACE2: the major cell entry receptor for SARS-CoV-2
Despite the unprecedented effort of the scientific community, the novel SARS-CoV-2 virus
has infected more than 46 million people worldwide, killing over one million two hundred …
has infected more than 46 million people worldwide, killing over one million two hundred …
[HTML][HTML] Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …
that patients with chronic respiratory disease were significantly under-represented in these …
[HTML][HTML] Covid-19 and COPD
JM Leung, M Niikura, CWT Yang… - European Respiratory …, 2020 - publications.ersnet.org
As of 11 July, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus responsible for the coronavirus disease 2019 (COVID-19) pandemic has infected over …
virus responsible for the coronavirus disease 2019 (COVID-19) pandemic has infected over …
Recent developments in the immunopathology of COVID‐19
There has been an important change in the clinical characteristics and immune profile of
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive …
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …